• search
For Quick Alerts
For Daily Alerts

WHO endorses tests by 3 research bodies, including ICMR


New Delhi, July 04: The World Health Organisation (WHO) has endorsed tests by three research bodies, including ICMR, for initial diagnosis of tuberculosis and detection of resistance to a drug most commonly used to treat the disease.

The three research bodies said their tests -- "rapid molecular Truenat assays -- have been endorsed by the global health body for initial diagnosis of tuberculosis and subsequent detection of rifampicin resistance in adults and children.

WHO endorses tests by 3 research bodies, including ICMR

Rifampicin is a standardized drug and the most commonly used first-line treatment of tuberculosis.

Validation of rapid antigen detection tests for COVID-19: ICMR invites applications from manufacturers

The three research bodies -- the Foundation for Innovative New Diagnostics (FIND), Molbio Diagnostics and the Indian Council of Medical Research said drug-resistant tuberculosis poses a particular challenge, with growing resistance to rifampicin and other drugs that treat the disease.

    Drunk Delhi cop runs over woman, Hero Cycles #BoycottChina plan & more news | Oneindia News

    Truenat is a novel molecular test that rapidly detects tuberculosis and rifampicin-resistance. All the three tests are run on the portable, battery-operated Truenat device and provide results in less than an hour, the bodies said in a joint statement.

    "Both Truenat MTB and Truenat MTB Plus (tests) detect Mycobacterium tuberculosis bacteria for TB diagnosis, while Truenat MTB-RIF Dx (test) identifies resistance to rifampicin, they said in the statement.

    Truenat MTB, Truenat MTB Plus and Truenat MTB-RIF are names of the tests endorsed by WHO.

    Noting that tuberculosis remains the leading cause of death from an infectious disease worldwide, with around 10 million cases and 1.5 million deaths in 2018, they said drug-resistant tuberculosis poses a particular challenge, with growing resistance to rifampicin and other drugs that treat the disease.

    "In 2018, around half-a-million new cases of rifampicin resistant TB were diagnosed. Urgent action is needed to close the gap in tuberculosis diagnosis and treatment, particularly in low-resource settings, to reach the WHO target of ending tuberculosis by 2030," the statement said.

    To that end, bringing sensitive TB diagnosis and drug susceptibility testing closer to patients is a key priority for global TB control, but requires robust point-of-care diagnostic tests that are easily implementable at lower levels of the healthcare system, it said.

    "This is a matter of pride for ICMR, Department of Health Research (DHR), New Delhi. It was a long journey to advance indigenous diagnostic technologies for diagnosis of tuberculosis and MDR/XDR-TB. Truenat is already accepted for use under the NTEP (National TB Elimination Program) in India.

    WHO says smoking linked to higher risk of coronavirus

    "Endorsement of Truenat by WHO will enable other low-and middle-income countries to procure Truenat for diagnosis of tuberculosis and rifampicin resistance, thus supporting tuberculosis elimination in developing countries," the statement quoting Balram Bhargava, Secretary DHR and Director General - ICMR said.

    For Daily Alerts
    Get Instant News Updates
    Notification Settings X
    Time Settings
    Clear Notification X
    Do you want to clear all the notifications from your inbox?
    Settings X
    We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more